Atopic Dermatitis
Dupixent approved in EU for infants, young children with severe atopic dermatitis
The European Commission approved Dupixent in the European Union for the treatment of severe atopic dermatitis in infants and young children who are candidates for systemic therapy, Sanofi and Regeneron announced in a press release.
VIDEO: Alphyn Biologics’ atopic dermatitis candidate shows positive early results
NEW ORLEANS — In this Healio video exclusive from the American Academy of Dermatology Annual Meeting, Neal Koller, founder and CEO of Alphyn Biologics, discusses the clinical-stage company’s drug pipeline.
Identifying atopic dermatitis molecular phenotype in African patients benefits treatment
NEW ORLEANS — In patients with atopic dermatitis, skin phenotypes were similar between East African and African American individuals in comparison with those of European American ethnicity, according to a presenter here.
VIDEO: Johnson & Johnson presents ‘wide breadth and depth’ of research at AAD 2023
NEW ORLEANS — Johnson & Johnson presented data in multiple areas at the American Academy of Dermatology Annual Meeting.
Dupilumab improves hand, foot atopic dermatitis in phase 3 study
NEW ORLEANS — Patients with hand and foot atopic dermatitis experienced significant improvement with dupilumab, which sustained an acceptable safety profile, according to phase 3 study results presented here.
Delgocitinib safe, efficacious in chronic hand eczema
NEW ORLEANS — Phase 3 trial results found delgocitinib cream to significantly improve patient and clinician-reported outcomes of hand eczema, according to a presenter at the American Academy of Dermatology Annual Meeting.
Rapid itch reduction reported with roflumilast cream in atopic dermatitis
NEW ORLEANS — Patients with atopic dermatitis experienced a rapid and sustained reduction in itch with topical roflumilast cream treatment, according to phase 3 study results presented at the American Academy of Dermatology Annual Meeting.
Real-life data shows dupilumab safe for Black patients with atopic dermatitis
NEW ORLEANS — Although Black patients with atopic dermatitis treated with dupilumab experienced fewer adverse events than their white counterparts, the difference did not reach statistical significance, according to a poster presented here.
Vtama cream exhibits ‘remarkable results’ in atopic dermatitis treatment
Results showed that Vtama cream 1% was safe, effective and well tolerated in a phase 3 study evaluating the cream in adults and children aged as young as 2 years with atopic dermatitis, Dermavant Sciences announced in a press release.
Training improves pediatricians’ eczema assessments before early peanut introduction
SAN ANTONIO — Training improved pediatricians’ adherence to guidelines for assessing eczema in infants before early peanut introduction, according to a presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.